Kaye Edward M. MD 4

What Happened
Edward M. Kaye, MD — a director of Cytokinetics, Inc. (CYTK) — was granted 151 shares of common stock on 2026-07-15. The filing reports an acquisition (award) at $82.62 per share, a total reported value of $12,476. This was an equity award issued in lieu of a cash director retainer and the shares were fully vested at grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-16 (timely filing).
• Transaction type/code: A — Award/Grant.
• Shares granted: 151 at $82.62/share; total value reported $12,476.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote: Shares granted pursuant to the Cytokinetics Equity in Lieu of Cash Retainer Program; shares are fully vested at grant.
• No 10b5-1 plan, tax-withholding, or sale reported in this filing.

Context
This is a routine compensation-related equity award to a director, rather than a market purchase or sale, and therefore should be viewed as compensation not a direct market endorsement. The grant value is modest (~$12.5k) relative to typical insider trading thresholds; it increases the director's stake but does not by itself signal material insider buying or selling.